Open for inclusion

Cancer type Title Country
Bladder cancer A phase II single arm clinical trial of nivolumab (BMS936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agent FI
Breast cancer A multicenter, multinational, Phase II study to evaluate Pertuzumab in combination with Trastuzumab and standard neoadjuvant Anthracycline-based chemotherapy in patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer NO
Breast cancer A Phase Ib/II Randomized Study of BI 836845 in Combination with Exemestane and Everolimus Versus Exemestane and Everolimus Alone in Women with Locally Advanced or Metastatic Breast Cancer SE
Breast cancer A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation NO
Breast cancer Intra-hepatic chemotherapy in patient with non-resectable liver mestastases from breast cancer. Only patients without extrahepatic disease are included DK
Breast cancer Intra-hepatic chemotherapy in patient with non-resectable liver metastases from breast cancer and limited extrahepatic disease DK
Breast cancer Phase Ib, open-label, multicenter dose-escalation study followed by an extension phase to evaluate the safety pharmacokinetics and activity of RO5479599 a glycoengineered antibody against HER3, administered incombination with pertuzumab and paclitaxel in DK
Breast cancer Phase Ib, Open-Label, Multicenter, Doseescalation Study followed by an Extension Phase to Evaluate the Safety, Pharmacokinetics and Activity of Ro5479599, a Glycoengineered Antibody Against Her3, Administered in combination with Pertuzumab and Paclitaxel DK
Cholangiocarcinoma A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of AmphinexTM induced Photochemical Internalisation (PCI) of Gemcitabine followed by Gemcitabine/ Cisplatin Chemotherapy in Patients with Advanced Inoperable Cholangioca NO
Colorectal cancer Effects of S-1 and Capecitabine in sombination with Oxaliplatine on the coronary artery blood flow in patients with metastatic gastrointestinal tract adenocarcinoma NO
Colorectal cancer Intra-hepatic and systemic chemotherapy with or without antibody for patients with non-resectable liver metastasis from solid tumours DK
Colorectal cancer Open-label , single-arm, phase II study of bevacizumab (Avastin) in combination with alternating Xeliri and Xelox as first-line treatment of patients with metastatic colorectal cancer FI
Colorectal cancer Potentially Resectable Metastatic Colorectal Cancer With Wild-type KRAS and BRAF: Alternating Chemotherapy Plus Cetuximab - A Randomised Phase II Trial NO
Gastric cancer Everolimus and temozolmide as first-line treatment in advanced gastrointestinal neuroendocrine carcinoma (G3) with a Ki67 of 20-55% NO
Gastric cancer Pazopanib in advanced gastrointestinal stromal tumors refractory to imatinib and sunutinib. A Non-comparative phase II multicenter study study by the Scandinavian Sarcoma Group FI
Glioblastoma Electrochemotherapy as a Palliative Treatment for Brain Metastases DK
Glioblastoma Phase 2 Study of Selinexor (KPT-330) in Patients With Recurrent Glioblastoma After Failure of Radiation and Temozolomide (KING) DK
Hematological malignancies A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 inPatients with Advanced Hematological Malignancies DK
Leukemia A multicenter open randomised phase II study of the efficacy and safety of azacitidine alone or in combination with lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotype including del(5q) DK
Leukemia A phase I multicenter open-label study of BGB324 as a single agent and in combination with cytarabine in patients with acute myeloid leukemia or high/intermediate (int-2) risk myelodysplastic syndrome wich overexpresses axl NO
Leukemia A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral lenalidomide to standard induction therapy in AML and RAEB ≥ 66 years and very poor risk AML ≥ 18 years. NO
Leukemia A safety and efficacy study of adding low dose pegylated IFN-alpha 2b to standard dose dasatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia DK
Lung cancer A phase I/IIa study of UV1 vaccination in patients with non-small cell lung cancer NO
Lung cancer A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology DK
Lung cancer Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination with Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects with Solid Malignancies and Deregulated FGF Pathway Signaling DK
Lung cancer Phase I Study of Single Agent MK-3475 in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma NO
Lymphoma Chemo-immunotherapy with early central nervous system (CNS) prophylaxis DK
Lymphoma Dose densified chemoimmunotherapy with early CNS prophylaxis in patients less than 65 years with high risk Diffuse Large B-Cell Lymphoma (NLG-LBC05) FI
Lymphoma Open-Label, Multi-Center, Phase 2 Study of Anti-CCR4 Monoclonal AntibodyKW-0761(mogamulizumab) in Subjects with Previously Treated Peripheral T-Cell Lymphoma (PTCL) DK
Lymphoma Open-label, uncontrolled phase II trial of intravenous PI3K inhibitor BAY-80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin´s lymphomas FI
Lymphoma Randomised phase II trial on primary chemotherapy with high-dose methtrexate and high-dose cytarabine with or without thiotepa, and with or without rituximab, followed by brain irradiation vs. high-dose chemotherapy supported by autologous stem cell trans DK
Lymphoma Rituximab plus lenalidomide or rituximab monotherapy for untreated patients with follicular lymphoma in need of therapy. A randomized, open-label, multicentre phase II trial FI
Lymphoma, Sarcoma Cross tumoral phase II clinical trial exploring crizotinib (PF-02341066) in patients with advanced tumors induced by causal alterations of ALK and/or MET NO
Melanoma A phase 1 study to evaluate safety, feasibility and immunologic response of adoptive T cell transfer with or without dendritic cell vaccination in patients with metastatic melanoma SE
Melanoma Safety and efficacy of intratumoural electrotransfer of Plasmid AMEP in patients suffering from advanced or metastatic melanoma: an open phase 1 trial DK
Melanoma Safety of UV1 vaccination in combination with ipilimumab in patients with unresectable or metastatic malignant melanoma NO
Melanoma T-cell therapy for patients with malignant melanoma DK
Melanoma The Melanoma Goup Trial: TOL + vemurafenib followed by interferon + vemurafenib maintenance (BRAF-positive patients) or TOL followed by interferon maintenance (BRAF-negative patients) FI
Melanoma Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma DK
Multiple diagnosis A first-in-human, multicenter, open-label, multiple ascending dose Phase I study in patients with advanced solid tumors to determine the safety, pharmacokinetics and pharmacodynamics of intratumorally administered ADC-1013 SE
Multiple diagnosis A phase I, open‐label, multi‐centre, multi‐dose, dose escalation study of LTX‐315 in patients with transdermally accessible tumours NO
Multiple diagnosis A Phase II, Open-label, Study in Subjects with BRAF V600E Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib NO
Multiple diagnosis Intra-hepatic and systemic chemotherapy with or without antibody for patients with non-resectable liver metastasis from solid tumours DK
Myeloma Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma DK
Ovarian cancer A phase II non comparative study with paclitaxel and carboplatin in combination with vorinostat in patients with advanced recurrent epithelia ovarian carcinoma DK
Pancreatic cancer Treatment of pancreatic adenocarcinoma by combining contrast agent and gemcitabine under sonication. NO
Prostate cancer DC-005 Prostate NO
Prostate cancer Dendritic cell vaccination in combination with Docetaxel for patients with prostate cancer – a randomized phase II study DK
Prostate cancer Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer (DUALIDES) FI
Solide tumores A phase I, multi-center, open-label, drug-drug interaction study to assess the effect of the CYP1A2 inhibitor, fluvoxamine, on dovitinib (TKI258) pharmacokinetics in patients with advanced solid tumors DK
Solide tumores A phase I/II , open-label study of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with advanced or metastatic solid tumors FI
Solide tumores A Phase II, Open-label, Study in Subjects with BRAF V600EMutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combiantion Therapy of Dabrafenib and Trametinib SE
Solide tumores A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Patients With Metastatic and/or Locally Advanced Malignant HER3-Positive Solid Tumors DK
Solide tumores An Open-label multicenter dose escalation phase 1 study with an expansion phase to evaluate safety pharmacokinetics and therapeutic activity of RO6895882 an immunocytokine consisting of a variant of interleukin-2 (IL-2v) targeting carcinoembryonic antigen DK
Solide tumores An Open-label Non-randomised Multicentre Comparative Phase I Studyof the Pharmacokinetics Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients with Advanced Solid Tumours and Normal Renal Function or Renal Impairment DK
Solide tumores An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification FI
Solide tumores An open-level, multicentre, dose-escalation, phase I study with an expansion phase, to evaluate safety, pharmacokinetics and therapeutic activity of RO6895882, an immunocytokine, consisting of a variant of interleukin-2 (IL-2v) targeting carcinoembryonic FI
Solide tumores Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers DK
Solide tumores HuMax®-TF-ADC Safety Study in Patients With Solid Tumors DK
Solide tumores Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Anti-Tumour Activity and Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients with Solid Cancer DK
Solide tumores Phase I dose-escalating study to evaluate the safety and tolerability of LiPlaCis (Liposomal Cisplatin formulation) in patients with advanced or refractory tumours DK
Solide tumores Safety and tolerability of single and repeated doses of ODM-203: an opel-label, non-randomized, uncontrolled, dose escalation, multicentre, first-in-human study in subjects with advanced solid tumors FI
Urothelial An exploratory Phase I Study with Sorafenib in Addition to Vinflunine in Progressive Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract SE